We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE Rejects Celegene’s Multiple Myeloma Drug Imnovid
NICE Rejects Celegene’s Multiple Myeloma Drug Imnovid
UK’s healthcare cost watchdog has recommended against coverage of Celegene’s multiple myeloma drug Imnovid, in combination with dexamethasone, for treating MM patients who have failed on at least two previous treatments and whose disease has progressed on the last therapy.